Rass K, Diefenbacher M, Tilgen W
Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum des Saarlandes, 66421, Homburg, Deutschland.
Hautarzt. 2008 Jun;59(6):475-83. doi: 10.1007/s00105-008-1556-5.
To treat malignant melanoma successfully currently means to recognize the tumor at an early stage and to remove it immediately. Aside from individual cases, available treatment modalities are not able to increase survival, especially in the palliative situation. Thus innovative experimental approaches are urgently needed to strongly improve the palliative and adjuvant treatment of melanoma. Anti-tumor effects are expected from targeted therapies, which are directed against defined molecules decisive for tumor pathogenesis. Crucial points of attack are signaling pathways, angiogenesis and apoptosis resistance. New diagnostic and therapeutic developments have enhanced the efficacy of chemotherapies. Increasing insights into tumor immunology provide new treatment approaches of vaccination, cell transfer and especially of blocking immune tolerance mechanisms. It will be challenging for the future to identify and characterize more precisely those patients who might most benefit from a certain treatment approach.
目前,成功治疗恶性黑色素瘤意味着在早期识别肿瘤并立即将其切除。除个别病例外,现有的治疗方式无法提高生存率,尤其是在姑息治疗的情况下。因此,迫切需要创新的实验方法来大幅改善黑色素瘤的姑息治疗和辅助治疗。靶向疗法有望产生抗肿瘤作用,这些疗法针对对肿瘤发病机制起决定性作用的特定分子。关键的攻击点是信号通路、血管生成和抗凋亡。新的诊断和治疗进展提高了化疗的疗效。对肿瘤免疫学的深入了解提供了疫苗接种、细胞转移尤其是阻断免疫耐受机制等新的治疗方法。未来,更精确地识别和表征那些可能从某种治疗方法中获益最大的患者将具有挑战性。